Clinical trial · Interventional
Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial
NCT05784766CI-TRIAL-00107344SARICactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with cancer have a higher incidence of AF but despite the higher incidence of AF in the cancer population, there are no randomized controlled trials (RCTs) for AF screening in this population. RCTs of AF screening in the general population have shown that screening can effectively detect AF earlier, and helps to identify candidates for appropriate anticoagulation that may lead to improvement in clinical outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 30-second ECG using the Kardia Mobile | Diagnostic Test | — | UNRESOLVED |
| routine care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Screen group
- description
- Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
- interventionNames
- Diagnostic Test: 30-second ECG using the Kardia Mobile
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.
- interventionNames
- Other: routine care
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female patients age ≥65 with a current diagnosis or history of cancer. 2. Patients currently undergoing or history of chemotherapy, radiotherapy or cancer related surgeries will be included. 3. The age is restricted to ≥65 years because prevalence of AF is extremely low. . Exclusion Criteria: 1. Known history of atrial fibrillation. 2. Non-English-speaking participants will not be enrolled
References
Publications (0)
Data not yet available
No reference posted for this study.